- iBio (IBIO) is a Texas-based company whose stock is up 496% year to date on investor optimism about its COVID-19 vaccine efforts.
- IBIO claims to have been involved in several vaccines for such high profile illnesses as H1N1 and Ebola, but the company never commercialized any of its vaccines or therapeutics.
- Despite this, IBIO's founder and president have collectively earned compensation in excess of 100% of IBIO's revenues since 2008.
- We do not believe that IBIO has the resources, track record, or management leadership to execute on its purported strategy, and assign a price target of $0.43 a share.
For further details see:
iBio: Another Vaccine Effort Unlikely To Materialize